glp-1 medications common side effects Infographic GLP-1 nausea: How to handle

2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)

Chen ZQ, Sun XH, Li XJ, Xu ZC, Yang Y, Lin ZY, et al

Therapeutic Dose (Pediatrics): In children with idiopathic GH deficiency, sermorelin has historically been dosed according to body weight

Wegovy (semaglutide) targets just one gut hormone, GLP-1